FK962

Research use only, not for human use.

FK962 is an somatostatin release enhancer exerts cognitive-enhancing actions.

FK962 is an somatostatin release enhancer exerts cognitive-enhancing actions.(In Vitro):FK962 (1 nM-1 μM) significantly enhances high K+-evoked somatostatin release from rat hippocampal slices. FK962 also significantly reduces somatostatin-induced inhibition of Ca2+ channels at 1-100 nM in single rat hippocampal neurons using whole-cell patch-clamp.(In Vivo):FK962 (0.1, 0.3 or 1.0 mg/kg; i.p.) and Donepezil (a single dose of 1 mg/kg) act synergistically to improve cognition in rats: as an add-on therapy for Alzheimer's disease.

FK962 (1 nM-1 μM) significantly enhances high K+-evoked somatostatin release from rat hippocampal slices. FK962 also significantly reduces somatostatin-induced inhibition of Ca2+ channels at 1-100 nM in single rat hippocampal neurons using whole-cell patch-clamp.

FK962 (0.1, 0.3 or 1.0 mg/kg; i.p.) and Donepezil (a single dose of 1 mg/kg) act synergistically to improve cognition in rats: as an add-on therapy for Alzheimer's disease. Animal Model:Male Lister Hooded rats, weighing approximately 270-300 Dosage:0.1, 0.3 or 1.0 mg/kg; Donepezil was given as a single dose of 1 mg/kg Administration:Administered i.p.Result:Resulted in minimal cognition enhancement when given separately. Combination showed a significantly greater effect on cognition.

——

Others

Other Targets

Somatostatin release

——

——

283167-06-6

264.3

C14H17FN2O2

>98% (HPLC)

In Vitro:?DMSO : 250 mg/mL (945.89 mM)

CC(=O)N1CCC(NC(=O)c2ccc(F)cc2)CC1

——

(-20℃)

With Ice Pack

≥ 2 years